Nestle looks to develop new products to serve users of weight-loss drugs

Nestle is developing specialized products for GLP-1 weight-loss drug users. Artificial intelligence aids in analyzing research and identifying nutrient combinations. These new offerings aim to address side effects like muscle loss and facial fat. The company is also exploring ingredients to manage post-treatment appetite increases. This strategic move transforms a potential threat into a significant business opportunity.